Social Anxiety Disorder
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
As defined in the DSM-IV-TR (1), social anxiety disorder (SAD), or social phobia, is now well recognized as a prevalent and significantly impairing disorder with an onset early in life. Since Liebowitz and colleagues' commentary regarding the neglect of SAD in the contemporary literature (2), there has been considerable research into the nature of SAD, its natural history, its biological and environmental underpinnings, and its treatment. There has also been concern about the pathologizing of normal temperamental variations. This concern is most commonly linked to the use of pharmacologic treatments, particularly in younger patients, and has been exacerbated by the debate about the safety of antidepressant treatment of children and adolescents (3). Epidemiologic studies show that SAD is among the most prevalent of all mental disorders. It is frequently comorbid with other anxiety disorders, mood disorders, and substance use disorders (4). It also remains undiagnosed and untreated for many years after onset. Few psychiatric disorders involve a debate about whether the condition in question should be regarded as a disorder and, if so, whether people with the condition should receive treatment for their distress. In the case of SAD, the debate extends to the question of whether the therapeutic approach with the largest data base regarding efficacy-namely, psychopharmacology-should be employed. Longitudinal investigations of children with behavioural inhibition show that many retain these temperamental and behavioural features as they develop (5) and that they have characteristics of social anxiety and avoidance. Untreated SAD does not usually remit. The educational, interpersonal and vocational pathways of subjects with social anxiety are frequently adversely affected. Early recognition and early intervention are being increasingly advocated in other disorders and deserve consideration for the child and adolescent suffering from anxiety. It has been found that few children identified as meeting criteria for SAD receive any treatment (6). In a sample of 190 parents, only 31% of the children who suffered from current anxiety disorder had received any treatment, compared with 40% of those with depression and 79% of those with attention-deficit hyperactivity disorder. With the exception of specific phobia, the commonest anxiety disorder was social phobia, which had a 1-year prevalence rate of 3.2% (standard error 1.3%) (6). The approach of intervening early begs the question of where the threshold is set for defining a case. Wakefield and colleagues (7) offer a provocative reexamination of social anxiety and its disorders, founded in a critique of the current DSM criteria. In their view, the number of true cases of SAD is markedly lower than epidemiologic studies based on DSM or ICD criteria recognize in community samples. These authors raise the concept of nondisordered social fears that cause suffering as a condition separate from what psychiatrists view as SAD. Should we reexamine the criteria for caseness? Will DSM-V take on that task? It has always appeared unlikely that marked increases in case recognition over brief periods of time reflect significant shifts in the actual prevalence of similarly defined cases. Thus SAD's current high prevalence (often quoted as 13.5%), compared with the fact that it was virtually unrecognized 20 years ago, reflects changes in awareness, in the criteria used for diagnosis, in the methods of screening for cases, and in the thresholds used to define caseness. If we cannot be reasonably sure of how to define cases, do we have sufficient evidence to recommend treatment? Our understanding of the efficacy of interventions in SAD is based on 2 streams of investigation: the common dichotomy of psychosocial and pharmacologic treatments, together with the combination of these treatments in willing subjects diagnosed with SAD according to DSM-III or DSM-IV criteria. …
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Cochrane Database of Systematic Reviews
(2008) · Encyclopedia of Public Health · doi:10.1007/978-1-4020-5614-7_436 · Cited by 4,527
Social Phobia: Review of a Neglected Anxiety Disorder
Liebowitz, M. R. (1985) · Archives of General Psychiatry · doi:10.1001/archpsyc.1985.01790300097013 · Cited by 577 · cited 1×
“Since Liebowitz and colleagues’ commentary regarding the neglect of SAD in the contemporary literature (2), there has been considerable research into the nature of SAD, its natural history, its biological and environmental underpinnings, and its treatment.”
Fergusson, D., Doucette, S., Glass, K. C., Shapiro, S., Healy, D., Hebert, P., & Hutton, B. (2005) · BMJ · doi:10.1136/bmj.330.7488.396 · Cited by 510
Child anxiety in primary care: Prevalent but untreated
Chavira, D. A., Stein, M. B., Bailey, K., & Stein, M. T. (2004) · Depression and Anxiety · doi:10.1002/da.20039 · Cited by 416 · cited 1×
“It has been found that few children identified as meeting criteria for SAD receive any treatment (6).”
Infant temperament and anxious symptoms in school age children
KAGAN, J., SNIDMAN, N., ZENTNER, M., & PETERSON, E. (1999) · Development and Psychopathology · doi:10.1017/s0954579499002023 · Cited by 284 · cited 1×
“Longitudinal investigations of children with behavioural inhibition show that many retain these temperamental and behavioural features as they develop (5) and that they have characteristics of social anxiety and avoidance.”
Wagner, K. D., Berard, R., Stein, M. B., Wetherhold, E., Carpenter, D. J., Perera, P., Gee, M., Davy, K., & Machin, A. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.11.1153 · Cited by 240 · cited 2×
“Since Stein and others’ review, evidence has accumulated about the efficacy of other SSRIs and serotonin norepinephrine reuptake inhibitors (SNRIs), including escitalopram (10,11), paroxetine (12,13), and venlafaxine (14).”
Pande, A. C., Feltner, D. E., Jefferson, J. W., Davidson, J. R. T., Pollack, M., Stein, M. B., Lydiard, R. B., Futterer, R., Robinson, P., Slomkowski, M., et al. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000117423.05703.e7 · Cited by 227 · cited 1×
“In an 11-week trial of adults with social phobia, pregabalin 600 mg daily was superior to placebo, whereas pregabalin 150 mg daily was not (17).”
Lines of Evidence on the Risks of Suicide with Selective Serotonin Reuptake Inhibitors
Healy, D. (2003) · Psychotherapy and Psychosomatics · doi:10.1159/000068691 · Cited by 220 · cited 1×
“This concern is most commonly linked to the use of pharmacologic treatments, particularly in younger patients, and has been exacerbated by the debate about the safety of antidepressant treatment of children and adolescents (3).”
EPIDEMIOLOGY, PATTERNS OF COMORBIDITY, AND ASSOCIATED DISABILITIES OF SOCIAL PHOBIA
Wïttchen, H., & Fehm, L. (2001) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(05)70254-9 · Cited by 176 · cited 1×
“It is frequently comorbid with other anxiety disorders, mood disorders, and substance use disorders (4).”
Venlafaxine Extended Release vs Placebo and Paroxetine in Social Anxiety Disorder
Liebowitz, M. R., Gelenberg, A. J., & Munjack, D. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.2.190 · Cited by 160 · cited 1×
“Venlafaxine extended release had efficacy comparable with that of paroxetine in a 12-week investigation, in contrast to placebo (15).”
Cited by
The treatment of social anxiety disorder
Rodebaugh, T. L., Holaway, R. M., & Heimberg, R. G. (2004) · Clinical Psychology Review · doi:10.1016/j.cpr.2004.07.007 · Cited by 424
Differences in social anxiety between men and women across 18 countries
Caballo, V. E., Salazar, I. C., Irurtia, M. J., Arias, B., & Hofmann, S. G. (2014) · Personality and Individual Differences · doi:10.1016/j.paid.2014.02.013 · Cited by 108
Kogan, C. S., Stein, D. J., Maj, M., First, M. B., Emmelkamp, P. M. G., & Reed, G. M. (2016) · Depression and Anxiety · doi:10.1002/da.22530 · Cited by 93
Social Phobia (Social Anxiety Disorder)
Andersson, G., & Carlbring, P. (2010) · Springer eBooks · doi:10.1007/978-1-4419-6510-3_6 · Cited by 80
Dechant, K., & Ellery, M. (2010) · Journal of Gambling Studies · doi:10.1007/s10899-010-9197-x · Cited by 64
Metadata
- Authors
- Swinson, R. P.
- Affiliations
- McMaster University (CA)
- Corresponding author
- Swinson, Richard P
- Venue
- The Canadian Journal of Psychiatry
- Publisher
- SAGE Publications
- Published
- 2005-05
- Volume
- 50
- Issue
- 6
- Pages
- 305-307
- ISSN
- 0706-7437 (ISSN-L)
- 1497-0015
- OpenAlex
- W285059606
- Cited by
- 17
- References
- 19
- Citations by year
- 2025: 1 · 2023: 1 · 2020: 1 · 2016: 2 · 2014: 2
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- The Canadian Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Social Sciences › Psychology › Clinical Psychology › Child and Adolescent Psychosocial and Emotional Development
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Keywords
- social anxiety disorder, children and adolescents, DSM-IV-TR diagnostic criteria, behavioral inhibition, comorbidities, treatment underuse, antidepressant safety, psychopharmacology, early intervention, prevalence, cognitive behavioral therapy, psychotherapy, school-based intervention
- MeSH terms
- Antidepressive Agents, Humans, Phobic Disorders, Severity of Illness Index, Diagnostic and Statistical Manual of Mental Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Social Anxiety Disorder. https://app.cochat.ai/papers/10.1177/070674370505000601
- The paper
- Swinson, R. P. (2005). Social Anxiety Disorder. The Canadian Journal of Psychiatry. https://doi.org/10.1177/070674370505000601
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.